Loading clinical trials...
Loading clinical trials...
An Open-Label Extension Study to Evaluate the Safety and Tolerability of QR 421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Helia)
Conditions
Interventions
RNA antisense oligonucleotide for intravitreal injection
Locations
7
United States
Center for Clinical Research Operations, Massachusetts Eye and Ear
Boston, Massachusetts, United States
University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan, United States
Casey Eye Institute, Oregon Health & Science University
Portland, Oregon, United States
Retina Foundation of the Southwest
Dallas, Texas, United States
Centre for Innovative Medicine, Department of Paediatric Surgery, Montreal Children's Hospital at the McGill University Health Centre
Montreal, Canada
Hôpital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles Génétique
Montpellier, France
Start Date
September 16, 2021
Primary Completion Date
October 18, 2022
Completion Date
October 18, 2022
Last Updated
August 7, 2024
NCT07548944
NCT05926583
NCT07174726
NCT07292987
NCT06789445
NCT04639635
Lead Sponsor
Laboratoires Thea
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions